Synthesis and optical properties of GdAlO:Eu, a red emitting phosphor with a strong negative thermal quenching effect.

For the purpose of obtaining red-light phosphors with excellent luminescence thermal stability, a series of GdAlO:Eu (GAO:Eu) phosphors were synthesized by combining the sol-gel method with high-temperature calcination, and a detailed series of study and analysis of their room temperature and high temperature luminescence properties was carried out. In GAO, the emission peaks corresponding to the D → F ( = 0, 1, 2, 3 and 4) transitions of Eu were observed at 578, 590, 610, 654, and 707 nm, with the strongest emission peak at 610 nm, and the obtained samples were red-light phosphors. The sample GAO:Eu synthesized by combining the sol-gel method with high-temperature calcination has a negative thermal quenching (NTQ) effect, and the best doped sample GAO:0.

Formation and enhancement of negative thermal quenching in emission of KGdF:Eu, Yb@GQDs.

In order to obtain a red emitting phosphor with good luminescence thermal stability, a series of KGdF:Eu, Yb@GQD (GQD: Cl-containing graphene quantum dots) red emitting phosphors have been synthesized by the co-precipitation method, and their luminescence thermal properties have also been studied in detail. It is intriguing that the negative thermal quenching (NTQ) effect is induced by the double doping of Yb, and the effect is further enhanced by GQD coating. The strongest integrated PL intensities of the optimal double doped sample and the optimal GQD-coated sample are at 130 and 170 °C, in which the corresponding integrated PL intensities are presented as 117.

No Increase in HIV Drug Resistance Mutations among Injecting Drug Users on Methadone Maintenance Therapy: A Prospective Cohort Study.

Background: Whether HIV-positive injecting drug users (IDUs) are at higher risk of developing drug resistance mutations (DRMs) after methadone maintenance therapy (MMT) than any other HIV-positive population is unclear.

Objective: To compare the incidence of new DRMs in two population groups: antiretroviraltreatment (ART) HIV-positive IDUs and non-drug users.

Methods: A prospective cohort of ART HIV-positive patients including IDUs who received MMT (MMT group) and non-drug users (N-MMT group) was established from April 2016 to December 2017 in Guangxi, China.

Effects of cotrimoxazole prophylaxis on infection in HIV/AIDS patients receiving antiretroviral therapy: a retrospective cohort study.

The dimorphic fungus (TM) is a common cause of HIV-associated opportunistic infections in Southeast Asia. Cotrimoxazole (CTX) inhibits folic acid synthesis which is important for the survival of many bacteria, protozoa, and fungi and has been used to prevent several opportunistic infections among HIV/AIDS patients. We question whether CTX is effective in preventing TM infection.